San Diego-primarily based Viking Therapeutics marked itself as a significant competitor from the weight loss drug industry in February after revealing promising information from the mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented to be a weekly injection As well as in Mar